{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T02:21:12Z","timestamp":1791512472072,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T00:00:00Z","timestamp":1468195200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40261-016-0433-8","type":"journal-article","created":{"date-parts":[[2016,7,11]],"date-time":"2016-07-11T05:24:36Z","timestamp":1468214676000},"page":"783-789","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5249-3650","authenticated-orcid":false,"given":"Yvan","family":"Jamilloux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Kerever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan","family":"Ferry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Broussolle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00f4me","family":"Honnorat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"S\u00e8ve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,11]]},"reference":[{"issue":"2","key":"433_CR1","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/ana.20933","volume":"60","author":"IJ Koralnik","year":"2006","unstructured":"Koralnik IJ. Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name? Ann Neurol. 2006;60(2):162\u201373.","journal-title":"Ann Neurol"},{"issue":"19","key":"433_CR2","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1212\/WNL.0b013e3181c0d4a1","volume":"73","author":"A Marzocchetti","year":"2009","unstructured":"Marzocchetti A, Tompkins T, Clifford DB, et al. Determinants of survival in progressive multifocal leukoencephalopathy. Neurology. 2009;73(19):1551\u20138.","journal-title":"Neurology"},{"issue":"8","key":"433_CR3","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/374048","volume":"36","author":"J Berenguer","year":"2003","unstructured":"Berenguer J, Miralles P, Arrizabalaga J, et al. Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis. 2003;36(8):1047\u201352.","journal-title":"Clin Infect Dis"},{"issue":"20","key":"433_CR4","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1212\/WNL.0b013e31821a446b","volume":"76","author":"P Vermersch","year":"2011","unstructured":"Vermersch P, Kappos L, Gold R, et al. Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology. 2011;76(20):1697\u2013704.","journal-title":"Neurology"},{"issue":"10","key":"433_CR5","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1136\/jnnp-2013-304897","volume":"84","author":"S Dahlhaus","year":"2013","unstructured":"Dahlhaus S, Hoepner R, Chan A, et al. Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. 2013;84(10):1068\u201374.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5700","key":"433_CR6","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF Elphick","year":"2004","unstructured":"Elphick GF, Querbes W, Jordan JA, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science. 2004;306(5700):1380\u20133.","journal-title":"Science"},{"issue":"1","key":"433_CR7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.3109\/15563650.2013.859264","volume":"52","author":"I Berling","year":"2014","unstructured":"Berling I, Isbister GK. Mirtazapine overdose is unlikely to cause major toxicity. Clin Toxicol. 2014;52(1):20\u20134.","journal-title":"Clin Toxicol"},{"issue":"15","key":"433_CR8","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1212\/WNL.0b013e31828c2fa1","volume":"80","author":"JR Berger","year":"2013","unstructured":"Berger JR, Aksamit AJ, Clifford DB, et al. PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section. Neurology. 2013;80(15):1430\u20138.","journal-title":"Neurology"},{"issue":"1","key":"433_CR9","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jclinepi.2013.08.003","volume":"67","author":"JJ Gagnier","year":"2014","unstructured":"Gagnier JJ, Kienle G, Altman DG, et al. The CARE guidelines: consensus-based clinical case report guideline development. J Clin Epidemiol. 2014;67(1):46\u201351.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"433_CR10","doi-asserted-by":"crossref","first-page":"e18506","DOI":"10.1371\/journal.pone.0018506","volume":"6","author":"A Haghikia","year":"2011","unstructured":"Haghikia A, Perrech M, Pula B, et al. Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders. PloS One. 2011;6(4):e18506.","journal-title":"PloS One"},{"issue":"10","key":"433_CR11","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1212\/WNL.0b013e318268465b","volume":"79","author":"S Gheuens","year":"2012","unstructured":"Gheuens S, Ngo L, Wang X, Alsop DC, Lenkinski RE, Koralnik IJ. Metabolic profile of PML lesions in patients with and without IRIS: an observational study. Neurology. 2012;79(10):1041\u20138.","journal-title":"Neurology"},{"issue":"2","key":"433_CR12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10096-013-1941-6","volume":"33","author":"JL Casado","year":"2014","unstructured":"Casado JL, Corral I, Garc\u00eda J, et al. Continued declining incidence and improved survival of progressive multifocal leukoencephalopathy in HIV\/AIDS patients in the current era. Eur J Clin Microbiol Infect. 2014;33(2):179\u201387.","journal-title":"Eur J Clin Microbiol Infect"},{"issue":"4","key":"433_CR13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.msard.2014.01.005","volume":"3","author":"RL Carruthers","year":"2014","unstructured":"Carruthers RL, Berger J. Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice. Mult Scler Relat Disord. 2014;3(4):419\u201330.","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"433_CR14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1007\/s13365-016-0427-6","volume":"22","author":"JR Berger","year":"2016","unstructured":"Berger JR, Fox RJ. Reassessing the risk of natalizumab-associated PML. J Neurovirol. 2016;22(4):533\u20135.","journal-title":"J Neurovirol."},{"issue":"4","key":"433_CR15","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1086\/315817","volume":"182","author":"A Luca De","year":"2000","unstructured":"De Luca A, Giancola ML, Ammassari A, et al. The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis. 2000;182(4):1077\u201383.","journal-title":"J Infect Dis"},{"issue":"19","key":"433_CR16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJM199805073381903","volume":"338","author":"CD Hall","year":"1998","unstructured":"Hall CD, Dafni U, Simpson D, et al. Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. N Engl J Med. 1998;338(19):1345\u201351.","journal-title":"N Engl J Med"},{"issue":"1","key":"433_CR17","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/QAI.0b013e31817bec64","volume":"49","author":"V Falc\u00f3","year":"2008","unstructured":"Falc\u00f3 V, Olmo M, del Saz SV, et al. Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study. J Acquir Immune Defic Syndr. 2008;49(1):26\u201331.","journal-title":"J Acquir Immune Defic Syndr"},{"issue":"6","key":"433_CR18","doi-asserted-by":"crossref","first-page":"e20967","DOI":"10.1371\/journal.pone.0020967","volume":"6","author":"J Gasnault","year":"2011","unstructured":"Gasnault J, Costagliola D, Hendel-Chavez H, et al. Improved survival of HIV-1-infected patients with progressive multifocal leukoencephalopathy receiving early 5-drug combination antiretroviral therapy. PloS One. 2011;6(6):e20967.","journal-title":"PloS One"},{"issue":"5","key":"433_CR19","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/hiv.12008","volume":"14","author":"F Fanjul","year":"2013","unstructured":"Fanjul F, Riveiro-Barciela M, Gonzalez J, et al. Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? HIV Med. 2013;14(5):321\u20135.","journal-title":"HIV Med"},{"issue":"6","key":"433_CR20","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s13365-015-0316-4","volume":"21","author":"T Dong-Si","year":"2015","unstructured":"Dong-Si T, Gheuens S, Gangadharan A, et al. Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy. J Neurovirol. 2015;21(6):637\u201344.","journal-title":"J Neurovirol"},{"issue":"9","key":"433_CR21","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1002\/art.34468","volume":"64","author":"ES Molloy","year":"2012","unstructured":"Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies. Arthritis Rheum. 2012;64(9):3043\u201351.","journal-title":"Arthritis Rheum"},{"issue":"20","key":"433_CR22","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","volume":"113","author":"KR Carson","year":"2009","unstructured":"Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834\u201340.","journal-title":"Blood"},{"issue":"2","key":"433_CR23","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ana.22408","volume":"70","author":"FJ Mateen","year":"2011","unstructured":"Mateen FJ, Muralidharan R, Carone M, et al. Progressive multifocal leukoencephalopathy in transplant recipients. Ann Neurol. 2011;70(2):305\u201322.","journal-title":"Ann Neurol"},{"issue":"Suppl 1","key":"433_CR24","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1002\/hup.388","volume":"17","author":"DJ Nutt","year":"2002","unstructured":"Nutt DJ. Tolerability and safety aspects of mirtazapine. Hum Psychopharmacol. 2002;17(Suppl 1):S37\u201341.","journal-title":"Hum Psychopharmacol"},{"issue":"3","key":"433_CR25","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0165-0327(98)00224-9","volume":"51","author":"J Fawcett","year":"1998","unstructured":"Fawcett J, Barkin RL. Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression. J Affect Disord. 1998;51(3):267\u201385.","journal-title":"J Affect Disord"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40261-016-0433-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-016-0433-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T14:10:41Z","timestamp":1498313441000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40261-016-0433-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,11]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["433"],"URL":"https:\/\/doi.org\/10.1007\/s40261-016-0433-8","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,11]]}}}